Renpho

The trillion dollar upside to longevity

Latest articles

The Sheekey Science Show: NAD+ rejuvenation strategies

NAD+ metabolism in aging & three strategies to rejuvenate. Welcome to The Sheekey Science Show! Longevity.Technology is delighted to partner with YouTube sensation Eleanor Sheekey (interviewed...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

BioAge kicks off Phase 2 longevity clinical trial

Company reveals primary indicator for BGE-117 clinical trial is unexplained anaemia of aging. Hot on the heels of its monster $90 million Series C funding...

Most read

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

Is nicotinamide riboside a safe and effective way to combat aging?

ChromaDex executive highlights the importance of clinical studies to prove the benefits of NAD+ boosting compound. ChromaDex is the company behind the popular healthy aging...
Apollo Neuro

Editor's picks

The Sheekey Science Show: NAD+ rejuvenation strategies

NAD+ metabolism in aging & three strategies to rejuvenate. Welcome to The Sheekey Science Show! Longevity.Technology is delighted to partner with YouTube sensation Eleanor Sheekey (interviewed...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...
Renpho

New economic model estimates that targeting aging has larger economic gains than eradicating individual diseases: time for a policy pivot?

Although life expectancy has increased over the last few years, there is an increment in the number of years spent in poor health [1]. Treatments targeting aging can lead to both healthier and longer lives. Therefore, there is a great emphasis on ‘healthy aging’ and a growing body of research focusing on its biological aspects [2].

Longevity.Technology: In a recent study, Andrew J Scott (London Business School), David Sinclair (Harvard Medical School) and Martin Ellison (University of Oxford) [3] evaluated the value of extending life expectancy, compressing morbidity and targeting aging. They took an economic perspective by using the value of statistical life (VSL) model, calibrated to current US economic, health, and demographic data.

Andrew J Scott (London Business School), David Sinclair (Harvard Medical School), Martin Ellison (University of Oxford)
L-R: Andrew J Scott (London Business School), David Sinclair (Harvard Medical School), Martin Ellison (University of Oxford)

This model allowed the researchers to place a monetary value on the financial gain from longer life, better health and changes in the rate at which we age [4,5]. VSL represents the sum of the value of each remaining year of life, discounted to the present day and weighted by the survival rate.

The study revealed that a compression of morbidity that improves health is more valuable than further increases in life expectancy. However, in order to raise economic gains, longevity has to improve too. Slowing down aging reduces the rate at which biological damage occurs and improves both health and mortality.

longevity $367tn

The authors calculated a slowdown in aging that increases life expectancy by one year is worth $38 trillion, and for ten years $367 trillion!

longevity explainer

How much can aging be realistically slowed? Is it more valuable to slow down aging or reduce specific diseases? A previous study [6] evaluated the impact of metformin – a drug used in the treatment of type 2 diabetes and that was found to protect against several age-related diseases [7] – on the incidence of various age-related comorbidities in diabetic men.

The results revealed a substantial reduction in the incidence of key age-related diseases, including dementia, cardiovascular disease, cancer and depression after five years of treatment. Due to the rising prevalence of age-related comorbidities, treatments targeting aging are valuable, as their impact will be felt across multiple diseases [8]. The study revealed that targeting aging has potentially larger economic gains than eradicating individual diseases.


 

… the US population is expected to see an increase in its average age of 4.0 years by 2050 and a decline of 1.6 million people … This effect is worth $256.7 billion for +1 year life …

 


 

Improvements in aging increase the average age of society, improve the quality of life in old age and increase the number of older people. Ellison, Scott and Sinclair [3] estimate that the US population is expected to see an increase in its average age of 4.0 years by 2050 and a decline of 1.6 million people. The data suggest that more people will be alive at older ages and in better health in 2050. This effect is worth $256.7 billion for +1 year life expectancy and $8.8 trillion for +10 years life expectancy. Investing in treatments targeting aging would have a positive impact on longevity, ultimately leading to gains in health and economy.

[1] https://pubmed.ncbi.nlm.nih.gov/33069325/
[2] https://us.macmillan.com/books/9781250230867
[3] https://tinyurl.com/3p582rsa
[4] https://www.journals.uchicago.edu/doi/abs/10.1086/379932
[5] https://www.nber.org/papers/w11405
[6] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5654524/
[7] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943638/
[8] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3938188/

Image credit: mohamed_hassan / Pixabay

Comment on this article

Christos Evangelou
Since the completion of his undergraduate and doctoral studies in Molecular Biosciences, Christos has been working in the medical communications industry, driven by his passion for communicating sciences. Apart from helping researchers to publish their studies, Christos writes articles related to sciences and medicine.
Renpho

Most popular

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

Is nicotinamide riboside a safe and effective way to combat aging?

ChromaDex executive highlights the importance of clinical studies to prove the benefits of NAD+ boosting compound. ChromaDex is the company behind the popular healthy aging...

It’s time to sit up and take notice of mitochondria

CohBar CEO on the development of a “true portfolio” of mitochondria based therapeutics. US biotech company CohBar is developing mitochondria-based therapeutics for the treatment of...
Apollo Neuro

Related articles

Leading NAD+ company ChromaDex announces $25m raise

LA-based company ChromaDex announces that it has entered into a securities purchase agreement for the sale of $25m of its common stock in a...

NIA announces funding for longevity clinical trials

New funding opportunity for longevity clinical trials from National Institute on Aging emphasises preventing aging and age-related disease. The NIA, which is part of the...

Andreessen Horowitz leads $7m seed funding: Bold

Digital health and wellness company bags $7 million in seed funding led by Andreessen Horowitz. Bold focuses on disease prevention and healthy aging. Using personalised and...

Charles River to acquire Cognate BioServices for $875m

Charles River Laboratories signs $875 million cash deal to acquire cell and gene manufacturer Cognate BioServices. Charles River has announced plans to acquire Cognate BioServices,...

$1.1B biotech SPAC good news for longevity

Bioengineered human tissue company Humacyte nears biotech SPAC deal to go public. Humacyte, a transformative biotech platform company capable of manufacturing universally-implantable bioengineered human tissue...
TruNigen pf